AstraZeneca announces results from EMERALD-1 Phase III trial of Imfinzi

Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca’s Imfinzi in combination with transarterial chemoembolisation, TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival, PFS, versus TACE alone in patients with hepatocellular carcinoma, HCC, eligible for embolisation. The trial continues to follow the secondary endpoint of overall survival, OS. Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “These positive results for Imfinzi-based treatment in EMERALD-1 may bring the potential of immunotherapy to patients with earlier stages of liver cancer. We look forward to discussing these data with regulatory authorities and seeing the survival data mature over time, which will be important as we aim to bring this novel treatment option to patients.” The safety profiles for Imfinzi and TACE plus bevacizumab were consistent with the known profile of each medicine, and there were no new safety findings. The data will be presented at a forthcoming medical meeting and shared with regulatory authorities.